{"organizations": [], "uuid": "0ceacd5e93a0be2396f9ec8e3847d866f75e930c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-selecta-biosciences-announces-fda/brief-selecta-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-lmb-100-and-svp-rapamycin-combination-therapy-idUSASB0BZFG", "country": "US", "domain_rank": 408, "title": "BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T15:12:00.000+02:00", "replies_count": 0, "uuid": "0ceacd5e93a0be2396f9ec8e3847d866f75e930c"}, "author": "", "url": "https://www.reuters.com/article/brief-selecta-biosciences-announces-fda/brief-selecta-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-lmb-100-and-svp-rapamycin-combination-therapy-idUSASB0BZFG", "ord_in_thread": 0, "title": "BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-selecta biosciences announces fda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nci", "sentiment": "none"}, {"name": "selecta biosciences inc", "sentiment": "none"}, {"name": "selecta biosciences inc", "sentiment": "none"}, {"name": "selecta biosciences", "sentiment": "none"}, {"name": "svp-rapamycin combination therapy reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / in 9 minutes BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy Reuters Staff 1 Min Read \nJan 2 (Reuters) - Selecta Biosciences Inc: \n* SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY \n* SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T15:12:00.000+02:00", "crawled": "2018-01-02T15:28:28.002+02:00", "highlightTitle": ""}